

2019 China Cancer Immunotherapy Workshop Agenda

June 29-30, 2019, Tianjin, China

June 29 (Saturday)		
Time	Topic	Speaker
08:30	Opening Remarks	
08:40-10:10	Plenary Keynote Talk	
08:40-09:10	Plenary Keynote Talk: Genome-wide search and evaluation of heterogenous targets for cancer immunotherapy	Lieping Chen (CAHON/Yale University)
09:10-09:40	Plenary Keynote Talk: In Situ Vaccination for cancer	Ronald Levy (Stanford University)
09:40-10:10	Plenary Keynote Talk: Paradigm Shift in Oncology Drug R&D: A Biopharma CEO's perspective	Kenji Yasukawa (VP of JPMA/President and CEO of Astellas)
10:10-10:20	Break	
10:20-11:50	Session 1: Principles of Cancer Immunology and immunotherapy	
10:20-10:50	Keynote Talk: The Molecular Cell Biology of Cancer Immunoediting and Cancer Immunotherapy	Robert Schreiber (Washington University)
10:50-11:20	Keynote Talk: Innate molecules and inflammatory cells in pre-metastatic niche formation and cancer metastasis	Xuetao Cao (Nankai University)
11:20-11:50	Keynote Talk: Effector T Cells, Tumor Ferroptosis and Immunotherapy	Weiping Zou (CAHON/Michigan University/AACR)
11:50-12:50	Session 2: IO Hot Topics: Immune Resistance and Combination Therapy	
11:50-12:20	Keynote Talk: Mechanisms and strategies in Overcoming resistance to anti-PD-1 therapy	Antoni Ribas (UCLA)
12:20-12:50	Keynote Talk: Immunotherapy combination	Zhen Su (CAHON/Merck EMD Serono)

12:50-13:50	Lunch	
13:50-15:30	Session 3: Emerging New Immunotherapy	
13:50-14:20	Keynote Talk: Approaches to target resistance to checkpoint inhibition	Lawrence Fong (UCSF)
14:20-14:50	Keynote Talk: Neoantigen Vaccination: Getting Personal for Cancer Immunotherapy	David Reardon (DFCI/Harvard)
14:50-15:10	Uncovering intracellular immune checkpoints for cancer immunotherapy	Zihai Li (CAHON/OSU)
15:10-15:30	Rational Design of Next-Generation Oncolytic Virus for cancer Immunotherapy	Liang Deng (CAHON & MSKCC/Cornell)
15:30-15:40	Break	
15:40-17:20	Session 4: Perspective from Biopharma Industry	
15:40-15:50	Roche pipeline	Jing He (Roche)
15:50-16:00	Recent Progress in Immuno-oncology Therapeutic Antibodies	Jingwu Zang (IMAB)
16:00-16:10	Checkpoint Blockade with Nivolumab and Ipilimumab: Recent Advances in GI Cancer	Ian Waxman (BMS)
16:10-16:20	Immuno-Oncology Clinical Development at Boehringer-Ingelheim	Michael Merger (BI)
16:20-16:30	Innovent's strategy for Cancer Immunotherapy	Michael Yu (Innovent)
16:30-16:40	Differential Biomarkers and Treatment Strategies for PD-1 pathway blockade-based Immunotherapy in China	Sheng Yao (Junshi)
16:40-16:50	Clinical Development of IO Drugs and China Landscape	Jianxin Yang (CStone)
16:50-17:00	Bi-specific antibody drug development for next generation of immuno oncology therapy	Michelle Yu Xia (Akeso)
17:00-17:10	Differentiated Strategy for Immuno-Oncology Drug Development	Zhaolong Gong (3D Medicines)
17:10-17:20	The innovative oncology pipeline at Zai Lab with an Immuno-Oncology focus	Yong-jiang Hei (Zai Lab)

June 30 (Sunday)					
Time	Topic				
09:00-10:30	Session 5&6 : Clinical Updates				
Session 5: Update on Checkpoint Inhibitors #1			Session 6: Update on Cellular Therapy #1		
Time	Topic	Speaker	Time	Topic	Speaker
09:00-09:30	Keynote Talk: Personalized immunotherapy for Non-Small Cell Lung Cancer: Sensitivity, Resistance, and Combinations	Roy Herbst (Yale University)	09:00-09:30	Keynote Speech: Adoptive T Cell Therapy for Solid Tumors	Cassian Yee (MD Anderson/CAHON)
09:30-09:50	GI IO Update	Andrew Zhu (CAHON/Harvard MGH)	09:30-09:50	CART in Hem Malignancies	Elizabeth Budde (CAHON/City of Hope NMC)
09:50-10:10	Lessons learned from failed IO trials	Lei Zheng (CAHON/Hopkins)	09:50-10:10	Efforts in Improving T Cell Therapy for Solid Tumors	Yangbing Zhao (CAHON/U Penn)
10:10-10:30	IO Toxicity management	Bo Lu (CAHON/Jefferson)	10:10-10:30	CART toxicities	Hongtao Liu (CAHON/U Chicago)
10:30-10:50	Break				
10:50-12:30	Session 5&6 : Clinical Updates				
Session 5: China Update on Checkpoint Inhibitors #2			Session 6: China Update on Cellular Therapy #2		
Time	Topic	Speaker	Time	Topic	Speaker
10:50-11:10	Lung cancer	Yilong Wu (Guangzhou/CSCO)	10:50-11:10	Clinical significances of autologous adoptive T cell Immunotherapy from 20 years experiences updates	Jun Ren (Capital Medical University)

				and consecutive perspectives	
11:10-11:30	Liver cancer	Yi Ba (Tianjian Cancer Hospital)	11:10-11:30	Robust bivalent CAR T treatment in B cell lineage malignancies	Weidong Han (PLA General Hospital)
11:30-11:50	Nasopharyngeal cancer	Yan Huang (Sun Yat-sen University Cancer Center)	11:30-11:50	Thinking of CART cells in treating lymphoma	Jun Zhu (Beijing University Cancer Hospital)
11:50-13:30	Lunch		11:50-12:30	Panelist discussion	Xiaojun Huang (Beijing University), Jianxiang Wang (Hematology Institute at CAMS), Depei Wu (Suzhou University)
			12:30-13:30	Lunch	
13:30-17:10	Session 7: Regulatory Considerations				
Parallel Sub-session 1:			Parallel Sub-session 2:		
Time	Topic	Speaker	Time	Topic	Speaker
13:30-14:00	Keynote Talk: EMA Regulations for IO drug accelerated approval	Francesco Pignatti (EMA)	13:30-14:00	Keynote Talk: FDA Regulations for Cellular Therapy Products	Ke Liu (FDA/CAHON)
14:00-14:30	Keynote Talk: FDA Regulations for IO drug accelerated approval	Max Ning (CAHON)	14:00-14:30	Keynote Talk: NMPA Regulations for Cellular Therapy Products	CDE
14:30-14:40	CDE General Considerations for Immunotherapy	Zhimin Yang (CDE)	14:30-15:00	Keynote Talk: EMA Regulations for ATMP	Francesco Pignatti (EMA)
14:40-15:00	CMC evaluation for IO drugs: From IND to NDA	Lina Song (CDE)	15:00-15:20	Cell Therapy regulations: clinical pharma aspect	Wei Wei (CDE)
15:00-15:20	ClinPharm and Toxicology evaluation for IO drugs	Liping Yan (CDE)	15:20-15:40	Cell Therapy regulations: Pre-clinical aspect	Min Zhang/Qingli Wang (CDE)
15:20-15:40	Statistical consideration of IO Trial	Jun Wang (CDE)	15:40-16:00	Cell Therapy regulations: clinical	Jianchao Gao (CDE)

	Trials			risk-management plan aspect	
15:40-16:00	Clinical review consideration of IO drugs	Ming Zhou (CDE)	16:00-16:20	Cell Therapy regulations: clinical review aspect	Yunhong Huang (CDE)
16:00-17:00	Panel Discussions		16:20-16:40	Cell Therapy regulations: clinical trial design and statistical aspect	Jianhong Pan (CDE)
			16:40-17:10	Panel Discussions	